Categorynews

Insights on the Peptide Therapeutics Global Market to 2030 – Key Industry Trends and Forecasts – ResearchAndMarkets.com

July 8, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 – 2030” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market.

Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world. Examples of recently approved peptide drugs include (in the reverse chronological order of approval) LupkynisT (2021), Mycappsa (2020), Scenesse (2019), Rybelsus (2019) and Vyleesi (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually.

Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry.

Companies Mentioned

13therapeutics
7 Med Health Ventures
9 Meters Biopharma
Abbott
Abingworth
Acorn Bioventures
ACT Capital Management
Adage Capital Management
Adams Street Partners
Advanced Accelerator Applications
Aileron Therapeutics
AJU IB Investment
Akashi Therapeutics
Alexion Pharmaceuticals
Allergan
Allysta Pharmaceuticals
Alphabet venture arm
Altimmune
Amgen
Amolyt Pharma
Ampio Pharmaceuticals
Amyndas Pharmaceuticals
Andera Partners
Angiochem
Anji Pharmaceuticals
AOP Orphan Pharmaceuticals
Apellis Pharmaceuticals
Apeptico
APIM Therapeutics
Apitope
Aquestive Therapeutics
Arch Biopartners
ARCH Venture Partners
Arix Bioscience
Asahi Kasei
AsclepiX Therapeutics
Astellas Pharma
AstraZeneca
Atlas Venture
Atox Bio
Aurinia Pharmaceuticals
Avilex Pharma
Avion Pharmaceuticals
Barer & Son Capital
Bayer
Becker
Belfius
Bergens forskningsstiftelse
Beth Israel Deaconess Medical Center
Better Ventures
Bicycle Therapeutics
Biogenosis
Bioglan
BioLineRx
Biolingus
BioMarin Pharmaceutical
Biomedical Advanced Research and Development Authority (BARDA)
BiomedInvest
BioMedPartners
Biomarck Pharmaceuticals
Bios Partners
Biosciences Research & Commercialization Center
BioSkin
BL&H
Boehringer Ingelheim
Boehringer Ingelheim Venture Fund
Boryung Pharmaceutical
Bossa Ventures
Boston Therapeutics
Bpifrance
Brightlands Life Sciences Ventures
Bristol Myers Squibb
Buttonwood
BVF Partners
Cambridge Innovation Capital (CIC)
Canaccord Genuity
Canadian Glycomics Network
CanBas
Cancer Research UK
Capital Community Angels
And Many More Companies!

One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

Who are the leading industry players engaged in the development of peptide therapeutics?
Which key disease indications are targeted by peptide therapeutic candidates in the current development pipeline?
What are the different initiatives undertaken by big pharma players for the development of peptide therapeutics in the recent past?
What kind of partnership models are most commonly adopted by stakeholders engaged in this domain?
Who are the key stakeholders that have actively made investments in the peptide therapeutics domain?
How is the current and future market opportunity likely to be distributed across key market segments?

For more information about this report visit https://www.researchandmarkets.com/r/8ove10